• 1
    Melief D. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58: 14375.
  • 2
    Townsend A, Trowsdale A. The transporters associated with antigen presentation. Semin Cell Biol 1993;4: 539.
  • 3
    Yewdell J, Bennink J. Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes. Adv Immunol 1992;52: 113.
  • 4
    Kovacsovics-Bankowski M, Rock K. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995;267: 2436.
  • 5
    Norbury C, Chambers B, Prescott A, Ljunggren H, Watts C. Constitutive macropinocytosis allows TAP-dependent presentation of exogenous antigen on class I MHC molecules by bone marrow derived dendritic cells. Eur J Immunol 1997;27: 2808.
  • 6
    Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15: 82150.
  • 7
    Steinman R, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993;329: 17.
  • 8
    Mayordomo J, Zorina T, Storkus W, Zitvogel L, Celluzzi C, Falo L, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicit protective and therapeutic antitumor immunity. Nat Med 1995;1: 1297302.
  • 9
    Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 291826.
  • 10
    Asheley D, Faiola B, Nair S, Hale L, Bigner D, Gilbao E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J Exp Med 1997;186: 117782.
  • 11
    Nair S, Snyder D, Rouse B, Gilbao E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70: 70615.
  • 12
    Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4: 32832.
  • 13
    Boczkowski D, Nair S, Nam J, Lyerly H, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60: 102834.
  • 14
    Eggert A, Schreurs M, Boerman O, Oyen W, Boer A, Punt C, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59: 33405.
  • 15
    Sogn J. Tumor immunology: the glass is half full. Immunity 1998;9: 757.
  • 16
    Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;91: 6458.
  • 17
    Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997;158: 1796802.
  • 18
    Cohen J. Apoptosis. Immunol Today 1993;14: 12630.
  • 19
    Bellone M, Lezzi G, Rovere P, Galati G, Ronchetti A, Protti M, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997;159: 53919.
  • 20
    Koh JS, Levine JS. Apoptosis and autoimmunity. Curr Opin Nephrol Hypertens 1997;6: 25966.
  • 21
    Boisteau O, Gautier F, Cordel S, Henry F, Harb J, Douillard J, et al. Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997;2: 40312.
  • 22
    Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188: 216373.
  • 23
    Rovere P, Vallinoto C, Bondanza A, Crosti M, Rescigno M, Ricciardi-Castagnoli P, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161: 446771.
  • 24
    Albert M, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392: 869.
  • 25
    Henry F, Bretaudeau L, Barbieux K, Meflah K, Gregoire M. Induction of antigen presentation by macrophages after phagocytosis of tumor apoptotic cells. Res Immunol 1998;149: 6739.
  • 26
    Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59: 332932.
  • 27
    Hoffmann T, Meidenbauer N, Dworacki G, Kanaya H, Whiteside T. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60: 35429.
  • 28
    Jenne L, Arrighi J, Jonuleit H, Saurat J, Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8 T cells for efficient tumor lysis. Cancer Res 2000;60: 444652.
  • 29
    Kimura AK, Xiang JH. High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants. J Natl Cancer Inst 1986;76: 124754.
  • 30
    Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 1999;42: 111.
  • 31
    Song W, Kong H, Carpenter H, Torii H, Granstein R, Rafii S, et al. Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186: 124756.
  • 32
    Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998;161: 551624.
  • 33
    Xiang J, Moyana T. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J Interferon Cytokine Res 2000;20: 34954.
  • 34
    Curiel-Lewandrowski C, Mahnke K, Labeur M, Roters B, Schmidt W, Granstein R, et al. Transfection of immature murine bone marrow-derived dendritic cells with the GM-CSF gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999;163: 17483.
  • 35
    Cross A, Richardson V, Ali S, Palmer I, Taub D, Rees R. Migration responses of human monocytic cell line to α- and β-chemokines. Cytokine 1997;9: 5218.
  • 36
    Majno G, Joris I. Apoptosis, oncosis and necrosis: an overview of cell death. Am J Pathol 1995;146: 315.
  • 37
    Labeur M, Roters B, Pers B, Mehling A, Luger T, Schwarz T, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162: 16875.
  • 38
    Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-α. J Exp Med 1994;179: 110918.
  • 39
    Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185: 31724.
  • 40
    Jonuleit H, Knop J, Enk A. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch Dematol Res 1996;289: 112.
  • 41
    Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27: 313542.
  • 42
    Pockaj B, Sherry R, Wei J, Yannelli J, Carter C, Leitman S, et al. Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 1994;73: 17317.
  • 43
    Guttinger M, Guidi F, Chinol M, Reali E, Veglia F, Viale G, et al. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 2000;60: 42115.
  • 44
    Xiang J, Chen Y, Moyana T. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther 2000;7: 102333.
  • 45
    Steinman R, Witmer M. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 1978;75: 51326.
  • 46
    Inaba K, Young J, Steinman R. Direct activation of CD8 cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987;166: 18294.
  • 47
    Rovere P, Sabbadini M, Vallinoto C, Fascio U, Zimmermann V, Bondanza A, et al. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol 1999;66: 3459.
  • 48
    Sauter B, Albert M, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of a cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191: 42333.
  • 49
    Rosenburg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4: 3217.
  • 50
    Murphy W, Tian Z, Asai O, Funakoshi S, Rotter P, Henry M, et al. 1996. Chemokines and T lymphocyte activation. II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J Immunol 1996;156: 210411.
  • 51
    Maric M, Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: linkage between inflammation and specific immunity. Cancer Res 1999;59: 554953.
  • 52
    Yamada S, Ikeda H, Yamazaki H, Shikishima H, Kikuchi K, Wakisaka A, et al. Cytokine-producing mammary carcinomas in transgenic rats carrying the pX gene of human T-lymphotropic virus type I. Cancer Res 1995;55: 25247.
  • 53
    Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996;2: 10905.
  • 54
    Lee L, Hellendall R, Wang Y, Haskill J, Mukaida N, Matsushima K, et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000;164: 276975.
  • 55
    Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces GM-CSF plus IL-4. Cancer Res 1996;56: 182833.
  • 56
    Hsieh C, Pang V, Chen D, Hwang L. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum Gene Ther 1997;8: 184354.
  • 57
    Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger J, et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human GM-CSF generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998;95: 131416.
  • 58
    Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998;392: 24552.
  • 59
    Dieu M, Vanbervliet B, Vicari A, Bridon J, Oldham E, Ait-Yahia S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188: 37386.
  • 60
    Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 1998;161: 10836.
  • 61
    Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. ERII/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161: 3096102.
  • 62
    Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3β are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162: 385964.
  • 63
    Gunn M, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams L, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189: 45160.
  • 64
    Hirao M, Onai N, Hiroishi K, Watkins S, Matsushima K, Robbins P, et al. CC chemokine receptor 7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000;60: 220917.